Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study.
Saved in:
| Title: | Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study. |
|---|---|
| Authors: | Bovenzi, Roberta (AUTHOR), Sancesario, Giulia Maria (AUTHOR), Conti, Matteo (AUTHOR), Grillo, Piergiorgio (AUTHOR), Cerroni, Rocco (AUTHOR), Bissacco, Jacopo (AUTHOR), Forti, Paolo (AUTHOR), Giannella, Emilia (AUTHOR), Pieri, Massimo (AUTHOR), Minosse, Silvia (AUTHOR), Ferrazzoli, Valentina (AUTHOR), Pucci, Noemi (AUTHOR), Laudazi, Mario (AUTHOR), Floris, Roberto (AUTHOR), Garaci, Francesco (AUTHOR), Pierantozzi, Mariangela (AUTHOR), Stefani, Alessandro (AUTHOR), Mercuri, Nicola Biagio (AUTHOR), Picchi, Eliseo (AUTHOR), Di Giuliano, Francesca (AUTHOR) |
| Source: | European Journal of Neurology. Jul2023, Vol. 30 Issue 7, p1983-1990. 8p. |
| Subjects: | Sex hormones, Parkinson's disease, Tau proteins, Magnetic resonance imaging, Globus pallidus, Male infertility |
| Abstract: | Background and purpose: Parkinson disease (PD) presents relevant sex‐related differences in epidemiology, pathophysiology, and clinical features, with males being more vulnerable to the disease. Sex hormones might have a role, as the experimental models suggest; however, human‐based evidence is scarce. Here, we integrated multimodal biomarkers to investigate the relationships between circulating sex hormones and clinical–pathological features in male PD patients. Methods: A cohort of 63 male PD patients underwent comprehensive clinical evaluation of motor and nonmotor disturbances; measurement of estradiol, testosterone, follicle‐stimulating hormone (FSH), and luteinizing hormone (LH) blood levels; and cerebrospinal fluid (CSF) assay of total α‐synuclein, amyloid‐β‐42, amyloid‐β‐40, total tau, and phosphorylated‐181 tau levels. A subgroup of 47 PD patients underwent brain volumetry by 3‐T magnetic resonance imaging for further correlations. A control group of 56 age‐matched individuals was enrolled for comparative analyses. Results: Male PD patients had higher estradiol and testosterone levels than controls. Estradiol had independent inverse associations with Movement Disorder Society–Unified Parkinson's Disease Rating Scale Part 3 score and disease duration; it was also lower in nonfluctuating patients. Testosterone had inverse independent correlations with CSF α‐synuclein and right globus pallidus volume. FSH and LH had age‐dependent correlations with cognitive impairment and CSF amyloid‐β‐42/amyloid‐β‐40 ratio. Conclusions: The study suggested that sex hormones could differentially contribute to clinical–pathological features of PD in male patients. Whereas estradiol might have a protective role in motor impairment, testosterone might be involved in male vulnerability to PD neuropathology. Gonadotropins instead might mediate age‐dependent phenomena of amyloidopathy and cognitive decline. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background and purpose: Parkinson disease (PD) presents relevant sex‐related differences in epidemiology, pathophysiology, and clinical features, with males being more vulnerable to the disease. Sex hormones might have a role, as the experimental models suggest; however, human‐based evidence is scarce. Here, we integrated multimodal biomarkers to investigate the relationships between circulating sex hormones and clinical–pathological features in male PD patients. Methods: A cohort of 63 male PD patients underwent comprehensive clinical evaluation of motor and nonmotor disturbances; measurement of estradiol, testosterone, follicle‐stimulating hormone (FSH), and luteinizing hormone (LH) blood levels; and cerebrospinal fluid (CSF) assay of total α‐synuclein, amyloid‐β‐42, amyloid‐β‐40, total tau, and phosphorylated‐181 tau levels. A subgroup of 47 PD patients underwent brain volumetry by 3‐T magnetic resonance imaging for further correlations. A control group of 56 age‐matched individuals was enrolled for comparative analyses. Results: Male PD patients had higher estradiol and testosterone levels than controls. Estradiol had independent inverse associations with Movement Disorder Society–Unified Parkinson's Disease Rating Scale Part 3 score and disease duration; it was also lower in nonfluctuating patients. Testosterone had inverse independent correlations with CSF α‐synuclein and right globus pallidus volume. FSH and LH had age‐dependent correlations with cognitive impairment and CSF amyloid‐β‐42/amyloid‐β‐40 ratio. Conclusions: The study suggested that sex hormones could differentially contribute to clinical–pathological features of PD in male patients. Whereas estradiol might have a protective role in motor impairment, testosterone might be involved in male vulnerability to PD neuropathology. Gonadotropins instead might mediate age‐dependent phenomena of amyloidopathy and cognitive decline. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.15801 |
